| 6.53 -0.31 (-4.53%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.11 | 1-year : | 12.04 |
| Resists | First : | 8.66 | Second : | 10.31 |
| Pivot price | 6.56 |
|||
| Supports | First : | 6 | Second : | 4.99 |
| MAs | MA(5) : | 6.84  |
MA(20) : | 6.8 |
| MA(100) : | 6.42 |
MA(250) : | 4.73 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 50.3 |
D(3) : | 54 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 10.31 | Low : | 2.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AGEN ] has closed above bottom band by 47.6%. Bollinger Bands are 47.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.09 - 7.14 | 7.14 - 7.18 |
| Low: | 6.6 - 6.65 | 6.65 - 6.68 |
| Close: | 6.77 - 6.85 | 6.85 - 6.91 |
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Mon, 02 Nov 2026
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat - BioSpace
Mon, 02 Nov 2026
Agenus Inc. (AGEN) Latest Stock News & Headlines - Yahoo Finance
Mon, 02 Nov 2026
After two-drug treatment, all 14 in one colon cancer group had 10% or less cancer left at surgery; 13 had none. - Stock Titan
Mon, 02 Nov 2026
Agenus Inc. (AGEN) options chain – Yahoo Finance - Yahoo Finance Singapore
Fri, 30 Oct 2026
Agenus Inc. (AGEN) Seasonal returns chart - Yahoo Finance UK
Fri, 30 Oct 2026
Agenus Inc. (AGEN) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 6.2 (%) |
| Held by Institutions | 46.4 (%) |
| Shares Short | 6,820 (K) |
| Shares Short P.Month | 6,690 (K) |
| EPS | 2.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.68 |
| Profit Margin | 69.3 % |
| Operating Margin | 32.7 % |
| Return on Assets (ttm) | 12.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 34.4 % |
| Gross Profit (p.s.) | 3.33 |
| Sales Per Share | 2.93 |
| EBITDA (p.s.) | 0.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -99 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | 2.53 |
| PEG Ratio | 1.4 |
| Price to Book value | -1.4 |
| Price to Sales | 2.22 |
| Price to Cash Flow | -3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|